title: [Application of the Multiple Sclerosis Functional Composite in Debrecen].
abstract: BACKGROUND
  The Multiple Sclerosis Functional Composite (MSFC) has been recommended by the National Multiple Sclerosis Society as a new clinical outcome measure. It is based on measurements in three clinical dimensions: leg function/ambulation (timed 25-foot walk), arm function (9-hole peg test), and cognitive function (paced auditory serial addition test). Scores on component measures are converted to standard scores (Z-scores) that reflect patient performance. This method has not yet been introduced into routine clinical practice.
  
  
  METHODS
  MSFC calculation was applied to 17 patients with relapsing-remitting multiple sclerosis (age mean: 37.4+/-10.8 years; duration of the disease: 5.5+/-4.9 years, EDSS: 2.7+/-1.4) seen at the neuroimmunological outpatient clinic to evaluate its usefulness and its correlation with the traditionally applied Expanded Disability Status Scale (EDSS) and with patient-reported quality of life. Fifteen patients received immunomodulatory treatment (interferon beta and glatiramer acetate). MSFC and EDSS were measured at 0, 3, 6, 9, 12, 18 months, and questionnaires on quality of life were filled in by the patients at 0, 6, 12, 18 months of follow-up.
  
  
  RESULTS
  The prospective study confirmed a strong correlation between EDSS and MSFC (Spearman correlation test, p=0.03, 0.004, 0.002, 0.004, 0.0008, 0.002; R=-0.54, -0.66, 0.68, -0.65, -0.73, -0.69) in multiple sclerosis. The MSFC was more sensitive to clinical changes than EDSS. The extent of changes on the two scales correlated only after 18 months (p<0.005, R=-0.65). The arm/hand function was the most sensitive measure for disease progression. There was no correlation between the quality of life and either of the two other clinical parameters.
  
  
  CONCLUSIONS
  MSFC is a simple method, suitable for follow-up of multiple sclerosis patients in everyday clinical practice.
authors.affiliation: Debreceni Egyetem, Altalános Orvostudományi Kar, Neurológiai Klinika, Debrecen.
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Mezei
authors.forename: Dániel
authors.initials: D
authors.lastname: Bereczki
authors.forename: László
authors.initials: L
authors.lastname: Csiba
authors.forename: Tünde
authors.initials: T
authors.lastname: Csépány
mesh_terms: D000328:Adult; D001132:Arm; D003071:Cognition; D004185:Disability Evaluation; D018450:Disease Progression; D005260:Female; D006801:Humans; D006814:Hungary; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy / Q000503:physiopathology* / Q000523:psychology*; D010045:Outpatients; D011446:Prospective Studies; D011788:Quality of Life; D011795:Surveys and Questionnaires; D013997:Time Factors; D016138:Walking
chemical_list: D007166:Immunosuppressive Agents